Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

ABSTRACT: This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy in participants with RAS-mutated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy in 4 Phase 2a tumor-specific cohorts.

DISEASE(S): Adenocarcinoma,Colorectal Cancer (crc),Pancreatic Adenocarcinoma,Melanoma,Advanced Cancer,Advanced Solid Tumor (phase 1),Non-small Cell Lung Cancer (nsclc),Malignant Melanoma (cutaneous)

PROVIDER: 2751815 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phosphoproteomics Profiling of Non-Small Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator

Project description:Activation of protein phosphatase 2A (PP2A) is a promising anti-cancer therapeutic strategy given this tumor suppressor’s ability to coordinately downregulate multiple pathways involved with growth and proliferation.Here, we studied the global signaling response signature of a novel small molecule activator of PP2A (SMAP). Through an exploration of the global phosphoproteomicalterations of two KRAS mutated non-small cell lung cancer (NSCLC) cell lines (A549 and H358)in the context of PP2A activation, we sought to identify the pathway-level perturbations and uncover candidate proteins that are potentially key targets of SMAP regulation.

2018-07-05 | PXD005698 | Pride

ChIP-chip from human liver cancer cells with HIF-2a

Project description:The transcription factor HIF-2a play an important role in the tumor progress, the aim is to explore the target genes of HIF-2a in liver cancer cell line. Chromatin immunoprecipitation (ChIP) of HIF-2a together with chromatin profiling by ChIP-on-chip analysis demonstrated that HIF-2a directly activates many target genes.

2012-04-12 | GSE37167 | GEO

ChIP-chip from human liver cancer cells with HIF-2a

2012-04-11 | E-GEOD-37167 | biostudies-arrayexpress

Shigella flexneri 2a strain:serotype 2a

Project description:Shigella flexneri 2a strain:serotype 2a Assembly

| PRJNA789735 | ENA

Shigella flexneri 2a strain:2a

Project description:Shigella flexneri 2a strain:2a Genome sequencing and assembly

| PRJNA379672 | ENA

RNAseq profiling of tumor, tumor-draining-lymph nodes, blood and tumor-associated macrophages of MC38 mice treated with the PI3Kg inhibitor AZD3458 and a combination of AZD3458 and anti-PD-1

Project description:RNAseq profiling of AZD3458 monotherapy and combination treatment with anti-PD-1 of whole tumors, isolated tumor macrophages (Mac) (CD45+CD11b+F4/80+), whole blood (PB) and tumor draining lymph nodes (TDLN) were assessed to elucidate further mechanisms leading to enhanced combination activity.

2021-02-28 | E-MTAB-10057 | biostudies-arrayexpress

Shigella flexneri 2a strain:serotype 2a

Project description:Shigella flexneri 2a strain:serotype 2a Genome sequencing

| PRJNA947612 | ENA

AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells

Project description:Phosphorylation of RNA polymerase II by cyclin-dependent kinase 9 (CDK9) is crucial for transcriptional regulation, and acute inhibition of CDK9 results in the rapid downregulation of genes with short-lived transcripts and labile proteins. Multiple non-selective CDK9 inhibitors have progressed clinically but were limited by a narrow therapeutic window. This work describes a novel, potent, and highly selective CDK9 inhibitor, AZD4573. Using integrated transcriptomic and proteomic analyses, loss-of-function pathway interrogation, and pharmacological comparisons, Mcl-1 depletion was identified as a major mechanism through which AZD4573 induces cell death in tumor cells. AZD4573 suppresses Mcl-1 in a dose- and time-dependent manner that causes caspase-3 cleavage in sensitive cancer cells, most notably in hematological malignancies. This pharmacodynamic response is observed in vivo as well, which leads to regressions in both subcutaneous tumor xenografts and disseminated models at tolerated doses as monotherapy or in combination with venetoclax. Fully understanding the mechanism, exposure, and anti-tumor activity of AZD4573 also informed the development of a robust PK/PD/efficacy model that helped select and predict the starting and efficacious dose range in man. Accordingly, AZD4573 is currently being evaluated in a phase I clinical trial for patients with hematological malignancies (clinicaltrials.gov identifier: NCT03263637).

2020-05-26 | PXD013796 | Pride

Transcriptomic modulation by adenosine 2A receptors in normal and endotoxemic myocardium

Project description:Analysis of venticular myocardium from adenosine 2A receptors (A2AR) knockouts following LPS stimulation. Results provide insight into the molecular components of A2AR mediated protection, but also reveal pathogenetic components of endotoxemic myocarditis as a result of LPS exposure. These findings demonstrate that intrinsic A2AR activity exerts limited transcriptional effects in unstressed heart, modifying G-coupled cAMP/PKA signal paths. LPS-dependent injury and dysfunction is associated with profound up-regulation of inflammatory/immune processes, fibrotic and cell death paths, and NF-kB, Erk/MAPK and JAK/Stat signaling, with shifts in multiple determinants of cardiac contraction and survival. Intrinsic A2AR activity modulates key aspects of these inflammatory responses, involving MAPK, JAK/Stat and NF-kB signaling Total RNA obtained from adenosine 2A receptor knockout or wild-type murine ventricular myocardium that were treated for 24 hours with either saline or lipopolysaccharide (n=4/group).

2013-05-01 | E-GEOD-44363 | biostudies-arrayexpress

Micrococcus sp. 2A strain:2A | isolate:Northwest Pacific Ocean

Project description:Micrococcus sp. 2A strain:2A | isolate:Northwest Pacific Ocean Genome sequencing

| PRJNA1103870 | ENA